Диссертация (1140655), страница 27
Текст из файла (страница 27)
– 2013 Feb. – Vol. 63(2). – P. 283-95.174104.Nitti V.W., Khullar V., van Kerrebroeck P. et al. Mirabegron for thetreatment of overactive bladder: a prespecified pooled efficacy analysis andpooled safety analysis of three randomised, double-blind, placebo-controlled,phase III studies // Int J Clin Pract. – 2013 Jul. – Vol. 67(7). – P. 619-32.105.Herbison P., Hay-Smith J., Ellis G., Moore K.
Effectiveness ofanticholinergic drugs compared with placebo in the treatment of overactivebladder: systematic review // BMJ. – 2003. – Vol. 326. – P. 841-844.106.Kessler T.M., Khan S., Panicker J.N. et al. In the human uroteliumand suburotelium, intradetrusor Botulinum neurotoxin type A does notinduce apoptosis: preliminary results // European Urology. – 2010. – Vol. 57.– P. 879 – 883.107.Chapple C., Sievert K.D., MacDiarmid S. Et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptomsand quality of life in patients with overactive bladder and urinaryincontinence: a randomised, double-blind, placebo-controlled trial //EurUrol. – 2013 Aug.
– Vol. 64(2). – P. 249-56.108.Lucas M.G., Bosch R.J., Burkhard F.C. et al. EAU guidelines onsurgical treatment of urinary incontinence // Eur Urol. – 2012 Dec. – Vol.62(6). – P. 1118-29.109.Nitti V.W., Dmochowski R., Herschorn S. et al. OnabotulinumtoxinAfor the treatment of patients with overactive bladder and urinaryincontinence: results of a phase 3, randomized, placebo controlled trial // JUrol. – 2013 Jun. – Vol. 189(6). – P.
2186-93.110.Мазо Е.Б., Кривобородов Г.Г.,Школьников М.Е., ЕфремовН.С. Ботулинический токсин в лечении урологических заболеваний //Урология. – 2007. – №2. – С.76-80.111.КривобородовГ.Г.Азбукаботулинотерапии:научно-практическое издание. Разд.: Ботулинотерапия в урологии; под ред.С.Л. Тимербаевой.
– М.: Практическая медицина, 20147 – 416 л.175112.Radziszewski P., Dobronski A., Borkowski A. Treatment of the non-neurogenic storage and voiding disorders with the chemical denervationcaused by botulinum toxin type A – a pilot study // Neurourol Urodyn. –2001. – Vol. 20. – P. 410-412.113.Schurch B., Stohrer M., Kramer G. et al. Botulinum toxin-A fortreating detrusor hyperreflexia in spinal cord injured patients: a newalternative to anticholinergic drugs // J.
Urol. (Baltimore). – 2000. – Vol.164. – P. 692-697.114.Cruz F., Herschorn S., Aliotta P. et al. Efficacy and safety ofonabotulinumtoxinA in patients with urinary incontinence due to neurogenicdetrusor overactivity: a randomised, double-blind, placebo-controlled trial //Eur Urol. – 2011 Oct. – Vol. 60(4). – P. 742-50.115.Fowler C.J., Auerbach S., Ginsberg D. et al.
OnabotulinumtoxinAimproves health-related quality of life in patients with urinary incontinencedue to idiopathic overactive bladder: a 36-week, double-blind, placebocontrolled, randomized, dose-ranging trial // Eur Urol. – 2012 Jul. – Vol.62(1). – P. 148-57.116.Васильев А.В. Внутридетрузорные инъекции ботулиническоготоксина типа А в лечении больных с идиопатической и нейрогеннойдетрузорной гиперактивностью, рефрактерной к антихолинергическойтерапии: Дисс. … канд. мед. наук: – М., 2010.
– 145 с.117.Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy andtolerability study of onabotulinumtoxinA for urinary incontinence fromneurogenic detrusor overactivity // J Urol. – 2012 Jun. – Vol. 187(6). – P.2131-9.118.Кривобородов Г.Г., Васильев А.В., Шумило Д.В. и соавт.Внутридетрузорные инъекции ботулинического токсина типа А убольных с гиперактивным мочевым пузырем //Урология. – 2010. – №3.– C. 36-40.176119.Smith C.P., Radziewski P., Borkowski A.
et al. Botulinum toxin A hasantinociceprive effect in treating interstitial cystitis //Urology. – 2004 Nov. –Vol. 64(5). – P. 871-5.120.Apostolidis A., Popat R., Yiangou Y. et al. Decreased sensoryreceptors P2X3 and TPRV1 in suburothelial nerve fibres followingintradetrusor injections of botulinum toxin for human detrusor overactivity //J Urol. –2005 Sep. – Vol.174(3). – P. 977-83.121.Groen J., Blok B.F., Bosch J.L. Sacral neuromodulation as treatmentfor refractory idiopathic urge urinary incontinence: 5-year results of alongitudinal study in 60 women // J Urol. – 2011 Sep. – Vol.186(3). – P. 9549.122.Spinelli M., Giardiello G., Gerber M.
et al. New sacralneuromodulation lead for percutaneous implantation using local anesthesia:description and first experience // J Urol. – 2003 Nov. – Vol. 170(5). – P.1905-7.123.Vandoninck V., van Balken M.R., Finazzi Argo E. et al. Percutaneustibial nerve stimulation in the treatment of overactive bladder: urodynamicdata // Neurol Urodyn. – 2003. – Vol.
22(3). – P. 227-32.124.МазоЕ.Б.,КривобородовГ.Г..Временнаясакральнаяитибиальная нейромодуляция в лечении больных гиперактивныммочевым пузырем // Вопросы нейрохирургии им. Н.Н.Бурденко. – 2002.– №1. – С.17 – 21.125.Неймарк А.И., Клыжина Е.А., Неймарк Б.А.. Чрескожнаятибиальная нейромодуляция в лечении женщин с гиперактивныммочевым пузырем. // Материалы Пленума Правления Российскогообщества урологов. – Тюмень. – 2005. – С. 389 – 390.126.Bemelmans B.L.H. Neuromodulation of the posterior tibial nerve(percSANS) for the treatment of lower urinary tract disfunction // EurUrology (suppl 2).
– 2000. – Vol. 37.– P.32.177127.Berghmans L.C., Van Waalwijk van Doorn E.S., Nieman F. et al.Efficacy of extramural physical therapy modalities in women with provenbladder overactivity: a randomized clinical trial // Neurourol Urodyn – 2000.– Vol. 19 (4). – P. 496 – 497.128.Erickson B.C., Bergman S., Eiknes S.H. Maximal electrostimulationof the pelvic floor in female idiopathic detrusor instability and urgeincontinence // Neurourol Urodyn. – 1989. – Vol. 8. – P.
219.129.Rosier P.F., Meuleman E.J., Debrujne F.M. Quality of life of patientswith lower urinary tract dysfunction after treatment with sacralneuromodulation // Neurourol Urodyn. – 1997. – Vol.16 (5). – P. 483 – 484.130.Stoller M.L. Afferent nerve stimulation for pelvic floor disfunction //Eur Urology(suppl 2). – 2000. – Vol. 37. – P.33.131.Zollner-Nielsen M., Samuelson S.M. Maximal electrical stimulationof patients with frequency, urgency and urge incontinence // Acta ObstetGynecol Scand.
– 1992. – Vol. 71. – P. 629.132.McGuire E.J., Zhang S., Horwinski E.R., Lytton B. Treatment ofmotor and sensory instability by electrical stimulation // J Urol. – 1983. –Vol. 129. – P. 78-79.133.Vandoninck V., van Balken M.R., Finazzi Argo E. et al. Percutaneustibial nerve stimulation in the treatment of overactive bladder: urodynamicdata // Neurol Urodyn. – 2003. – Vol. 22(3). – P. 227-32.134.Tanagho E.A., Schmidt R.A., Orvis B.R. Neural stimulation forcontrol of voiding dysfunction: a preliminary report in 22 patients withserious neuropathic voiding disorders // J Urol.
–1998. – Vol. 142. – P. 340345.135.Amend B., Matzel K.E., Abrams P et al. How does neuromodulationwork // Neurol Urodyn. – 2011 Jun. – Vol. 30(5). – P. 762-5.136.Bower W.F., Moore K.H., Adams R.D., Shepherd R. A urodynamicstudy of surface neuromodulation versus sham in detrusor instability andsensory urgency // J Urol. – 1998 Dec. – Vol. 160 (6 Pt 1). – P. 2133-6.178137.Клинические рекомендации European Association of Urology,2014.138.Appell R.A. Overactive bladder in special patient populations // RevUrol (Suppl 8):. – 2003. – Vol.5. – P. 37-41.139.Cameron A.P., Clemens J.Q., Latini J.M. et al.
Combination drugtherapy improves compliance of the neurogenic bladder // J Urol. – 2009Sep. – Vol. 182(3). – P. 1062-7.140.Horstmann M., Schaefer T., Aguilar Y. et al. Neurogenic bladdertreatment by doubling the recommended antimuscarinic dosage // NeurourolUrodyn. – 2006. – Vol. 25(5). – P. 441-5.141.Menarini M., Del Popolo G., Di Benedetto P. et al; TcP128-StudyGroup. Trospium chloride in patients with neurogenic detrusor overactivity:is dose titration of benefit to the patients? // Int J Clin Pharmacol Ther. –2006 Dec. – Vol. 44(12).
– P. 623-32.142.Nardulli R., Losavio E., Ranieri M., et al. Source Combinedantimuscarinics for treatment of neurogenic overactive bladder // Int JImmunopathol Pharmacol(1 Suppl). – 2012 Jan-Mar. - Vol. 25. – P. 35-41.143.Bennett N., O’Leary M., Patel A.S. et al. Can higher doses ofoxybutynin improve efficacy in neurogenic bladder? // J Urol. – 2004 Feb.
–Vol. 171(2 Pt 1). – P. 749-51.144.De Paiva A., Meunier F. A., Molgo J. et al.Functional repair of motorendplates after botulinum neurotoxin type A poisoning: biphasic switch ofsynaptic activity between nerve sprouts and their parent terminals // ProcNatl Acad Sci U S A. – 1999. – Vol. 96. – P. 3200–3205.145.Xinhua W., Xiaofu T., Liying C. et al. Remote effects of localinjection of botulinum toxin type A // Acta Academiae Medicinae Sinica. –1999/ - Vol. 12(5).
– P. 362.146.Аль-Шукри С.Х., Кузьмин И.В. Солифенацин в лечении больныхс гиперактивным мочевым пузырем // Урология. – 2007. - №3. – C. 1921.179147.Amend B., HennenlotterJ., Schäfer T. et al. Effective treatment ofneurogenic detrusor dysfunction by combined high-dosed antimuscarinicswithout increased side-effects // Eur Urol. – 2008 May. – Vol. 53(5). – P.1021-8.148.Abrams P., Andersson K.E., Buccafusco J.J.et al. Muscarinicreceptors: their distribution and function in body systems, and theimplications for treating overactive bladder // Br J Pharmacol. – 2006.
– Vol.148. – P. 565–578.149.Hedge S.S. Muscarinic receptors in the bladder: from basic research totherapeutics // Br J Pharmacol (Suppl). – 2006. – Vol. 147. – P. 80-87.150.Vizzard M.A. Changes in urinary bladder neurotrophic factor mRNAand NGF protein following urinary bladder dysfunction //Exp Neurol. –2000.– Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
